News & Updates

Show Multimedia Only
Osilodrostat curbs hypercortisolism in most patients with adrenal CS Osilodrostat curbs hypercortisolism in most patients with adrenal CS

Osilodrostat curbs hypercortisolism in most patients with adrenal CS

29 Jul 2026 byStephen Padilla

Use of osilodrostat is effective at controlling hypercortisolism in one of three (66.7 percent) patients with adrenal Cushing's syndrome (CS) treated for longer than 4 weeks and in nearly four of five (87.5 percent) individuals treated for more than 12 weeks, a real-world study has shown. It also displays a positive impact on blood pressure and body weight.

29 Jul 2026
Which anti-obesity drug is safest, most effective?

Which anti-obesity drug is safest, most effective?

27 Jul 2026 byStephen Padilla

Among available drugs for obesity, tirzepatide and cagrilintide-semaglutide (CagriSema) yield the largest decrease in body weight, regardless of diabetes status, suggest the results of a systematic review and network meta-analysis.

27 Jul 2026
Older age, overweight raise risk of symptomatic VTE in DFF patients

Older age, overweight raise risk of symptomatic VTE in DFF patients

16 Jul 2026 byStephen Padilla

A Singapore study has observed a high prevalence of symptomatic venous thromboembolism (VTE) in patients who underwent distal femur fracture (DFF) surgery. Those with advanced age or who are overweight are more likely to develop symptomatic VTE.

16 Jul 2026